271 related articles for article (PubMed ID: 31465533)
1. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
[TBL] [Abstract][Full Text] [Related]
2. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Lacroix A; Bronstein MD; Schopohl J; Delibasi T; Salvatori R; Li Y; Barkan A; Suzaki N; Tauchmanova L; Ortmann CE; Ravichandran S; Petersenn S; Pivonello R
J Endocrinol Invest; 2020 Nov; 43(11):1613-1622. PubMed ID: 32385851
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Petersenn S; Salgado LR; Schopohl J; Portocarrero-Ortiz L; Arnaldi G; Lacroix A; Scaroni C; Ravichandran S; Kandra A; Biller BMK
Endocrine; 2017 Jul; 57(1):156-165. PubMed ID: 28597198
[TBL] [Abstract][Full Text] [Related]
6. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Feelders RA; Fleseriu M; Kadioglu P; Bex M; González-Devia D; Boguszewski CL; Yavuz DG; Patino H; Pedroncelli AM; Maamari R; Chattopadhyay A; Biller BMK; Pivonello R
Front Endocrinol (Lausanne); 2023; 14():1165681. PubMed ID: 37876540
[TBL] [Abstract][Full Text] [Related]
8. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
Newell-Price J; Pivonello R; Tabarin A; Fleseriu M; Witek P; Gadelha MR; Petersenn S; Tauchmanova L; Ravichandran S; Gupta P; Lacroix A; Biller BMK
Eur J Endocrinol; 2020 Feb; 182(2):207-217. PubMed ID: 31804965
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.
Manetti L; Deutschbein T; Schopohl J; Yuen KCJ; Roughton M; Kriemler-Krahn U; Tauchmanova L; Maamari R; Giordano C
Pituitary; 2019 Oct; 22(5):542-551. PubMed ID: 31440946
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
MacKenzie Feder J; Bourdeau I; Vallette S; Beauregard H; Ste-Marie LG; Lacroix A
Pituitary; 2014 Dec; 17(6):519-29. PubMed ID: 24287689
[TBL] [Abstract][Full Text] [Related]
11. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
[TBL] [Abstract][Full Text] [Related]
12. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Findling JW; Fleseriu M; Newell-Price J; Petersenn S; Pivonello R; Kandra A; Pedroncelli AM; Biller BM
Endocrine; 2016 Nov; 54(2):516-523. PubMed ID: 27209465
[TBL] [Abstract][Full Text] [Related]
13. The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".
Pivonello R; Arnaldi G; Scaroni C; Giordano C; Cannavò S; Iacuaniello D; Trementino L; Zilio M; Guarnotta V; Albani A; Cozzolino A; Michetti G; Boscaro M; Colao A
Endocrine; 2019 Jun; 64(3):657-672. PubMed ID: 30968338
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
[TBL] [Abstract][Full Text] [Related]
15. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Boscaro M; Bertherat J; Findling J; Fleseriu M; Atkinson AB; Petersenn S; Schopohl J; Snyder P; Hughes G; Trovato A; Hu K; Maldonado M; Biller BM
Pituitary; 2014 Aug; 17(4):320-6. PubMed ID: 23943009
[TBL] [Abstract][Full Text] [Related]
16. Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.
Samson SL
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):445-50. PubMed ID: 25003365
[TBL] [Abstract][Full Text] [Related]
17. Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.
Trementino L; Cardinaletti M; Concettoni C; Marcelli G; Boscaro M; Arnaldi G
Pituitary; 2015 Jun; 18(3):359-65. PubMed ID: 24952218
[TBL] [Abstract][Full Text] [Related]
18. The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.
Trementino L; Zilio M; Marcelli G; Michetti G; Barbot M; Ceccato F; Boscaro M; Scaroni C; Arnaldi G
Endocrine; 2015 Sep; 50(1):154-61. PubMed ID: 25500791
[TBL] [Abstract][Full Text] [Related]
19. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.
Webb SM; Ware JE; Forsythe A; Yang M; Badia X; Nelson LM; Signorovitch JE; McLeod L; Maldonado M; Zgliczynski W; de Block C; Portocarrero-Ortiz L; Gadelha M
Eur J Endocrinol; 2014 Jul; 171(1):89-98. PubMed ID: 24760537
[TBL] [Abstract][Full Text] [Related]
20. Psychometric evaluation of the Cushing's Quality-of-Life questionnaire.
Nelson LM; Forsythe A; McLeod L; Pulgar S; Maldonado M; Coles T; Zhang Y; Webb SM; Badia X
Patient; 2013; 6(2):113-24. PubMed ID: 23575965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
